A detailed history of Alps Advisors Inc transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 44,562 shares of INZY stock, worth $133,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,562
Previous 48,263 7.67%
Holding current value
$133,240
Previous $215,000 8.37%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.31 - $6.0 $15,951 - $22,206
-3,701 Reduced 7.67%
44,562 $233,000
Q2 2024

Aug 13, 2024

BUY
$4.33 - $7.31 $20,363 - $34,378
4,703 Added 10.8%
48,263 $215,000
Q1 2024

May 14, 2024

BUY
$4.14 - $7.66 $5,568 - $10,302
1,345 Added 3.19%
43,560 $333,000
Q4 2023

Feb 14, 2024

BUY
$2.71 - $4.5 $114,402 - $189,967
42,215 New
42,215 $179,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $120M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.